Review

Peptide Conjugation via CuAAC 'Click' Chemistry

Abdullah A. H. Ahmad Fuaad [1], Fazren Azmi [1], Mariusz Skwarczynski [1] and Istvan Toth [1,2,*]

[1] School of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, QLD 4072, Australia; E-Mails: abdullah.ahmadfuaad@uqconnect.edu.au (A.A.H.A.F.); fazren.azmi@uqconnect.edu.au (F.A.); mariusz.skwarczynski@uq.edu.au (M.S.)

[2] School of Pharmacy, University of Queensland, Woolloongabba, QLD 4012, Australia

* Author to whom correspondence should be addressed; E-Mail: i.toth@uq.edu.au; Tel.: +61-733-469-892; Fax: +61-733-654-273.

Abstract: The copper (I)-catalyzed alkyne azide 1,3-dipolar cycloaddition (CuAAC) or 'click' reaction, is a highly versatile reaction that can be performed under a variety of reaction conditions including various solvents, a wide pH and temperature range, and using different copper sources, with or without additional ligands or reducing agents. This reaction is highly selective and can be performed in the presence of other functional moieties. The flexibility and selectivity has resulted in growing interest in the application of CuAAC in various fields. In this review, we briefly describe the importance of the structural folding of peptides and proteins and how the 1,4-disubstituted triazole product of the CuAAC reaction is a suitable isoster for an amide bond. However the major focus of the review is the application of this reaction to produce peptide conjugates for tagging and targeting purpose, linkers for multifunctional biomacromolecules, and reporter ions for peptide and protein analysis.

1. Introduction

Peptides and proteins were discovered in the beginning of the 20th century. However, it took more than 50 years for scientists to understand their natural biosynthesis pathway. In cells, the biosynthesis of peptides and proteins starts with the transcription of deoxyribonucleic acid (DNA) sequences to

ribonucleic acid (RNA) sequences, which is also known as messenger RNA (mRNA). These mRNA transcripts are translated into peptides or proteins in the ribosome. In this biological 'mechanical' ligation factory within living cells, amino acids are conjugated to one another with the help of transfer RNA (tRNA). The resultant proteins perform crucial roles in living organisms, serving as enzymes, structural proteins, signaling proteins *etc*. The broad spectrum of biological activities has made proteins an attractive component of modern pharmaceutics. For example, insulin,used as a drug to control blood sugar level in patients with Type 1 diabetes, was originally extracted from cows and pigs, purified and used in humans as a therapeutic drug [1]. To improve this process, scientists have tried to mimic the conjugation process *in vitro*. Chemical peptide synthesis began when Theodor Curtius succeeded in conjugating the first N-protected dipeptide, benzoylglycylglycine, in 1881 [2]. Twenty years later, Emil Fisher published an alternative glycylglycine dipeptide synthesis via a hydrolysis pathway [3]. Since then, interest in peptide synthesis grew and with the introduction of temporary protecting groups such as carbobenzoxy (Cbz) by Bergmann and Zerwas in 1931 [4], the synthesis of the first biologically active peptide hormone (oxytocin) was accomplished by Vigneaud *et al*. [5]. Finally, peptide synthesis was streamlined with the introduction of solid support (also called solid phase peptide synthesis or SPPS) by Merrifield in the early 1960s [4,6]. The SPPS approach allowed the synthesis of complex, chemically synthesized biological active peptides such as human insulin and ribonuclease A enzyme [4,7]. Peptides up to 50 amino acids in length can be efficiently synthesized by SPPS in a relatively short time. Major drawbacks of SPPS were observed for the synthesis of longer peptide (>50 amino acids) where the solubility of the growing peptide and accumulation of by-products on the solid support resulted in poor purity and yield [6].

New chemical synthesis techniques were then developed to combine two or more peptide fragments to form a longer construct. For example, Kimura *et al*. in 1981 used a segment condensation reaction technique where 13 fragments of five amino acid long peptides (each with protected side chain) were conjugated together in water to form a functional protein [8]. This reaction is typically limited by epimerization of enantiomerically active residues at the C-terminus of the peptide during carboxyl group 'activation' prior to the condensation reaction. Additionally, the presence of protected side chains was required to avoid by-product formation due to the reaction of side chain functional groups. The method was extremely tedious and produced a very poor yield of the final product.

In the same year, a "prior thiol capture" reaction was introduced by Kemp *et al*. The group reported intramolecular *O,N*-acyl transfer with disulfide interchange to transfer an adjacent acetyl group to an amine group at the N-terminal of a cysteine peptide residue, illustrated in Scheme 1 [9]. However, the method has its own limitations: new disulfide bond formation is slow and the whole process resulted in the formation of byproducts.

A more advantageous chemical technique called native chemical ligation (NCL) was introduced by Wieland *et al*. in 1953. However, a practical method was not reported, until Kent and co-workers introduced their developments on the technique in the 1990s [6,10,11]. NCL involves the conjugation of a C-terminal thioester peptide to an N-terminal cysteinyl peptide (Scheme 2). This technique was much more efficient in comparison to the approaches previously mentioned, as protection of peptide side chains was not required and final product was produced in high yield and purity. However, the peptide of interest needed to contain a cysteine residue (or its derivatives) within its native sequence, otherwise additional process of desulfurization is required to remove the 'unwanted' sulfur group [11,12].

Consequently, during the desulfurization, other sulfur moieties within the peptide construct, if present, must withstand the desulfurization process or else, the sulfur groups will be removed and will resulted in undesired peptide construct [12]. Although NCL is an exceptionally effective method for the production of large peptides and proteins, there were also difficulties encountered during the ligation of hydrophobic target products [13,14]. Additionally, NCL has also been difficult to apply as a conjugation technique between peptides and non-peptidic molecules such as polymer. Thus alternative methods such as Staudinger ligation, Diels-Alder reaction, strain promoting alkyne-azide cycloaddition (SPAAC) and copper catalyzed alkyne-azide cycloaddition reaction (CuAAC) have been developed for further modification of peptides modification.

Scheme 1. Prior thiol capture involving intramolecular *O,N*-acyl transfer reaction. (**A**) Activated thiol species (**B**) captured thiol fragment, and (**C**) after acyl transfer reaction, (**D**) desired peptide is formed.

Scheme 2. An example of NCL reaction of peptides containing cysteine or its derivatives. Reaction (**A**) intermolecular thioesterification; (**B**) intramolecular S→N acyl transfer; (**C**) (optional) desulfurization of cysteine derivatives to cysteine residue.

This review presents advances in the conjugation of peptides to other biomolecules via CuAAC to form 1,4-disubstituted 1,2,3-triazoles. CuAAC is used as an alternative to NCL, the bioconjugation technique widely used in protein and peptide chemistry. This review briefly described the history of CuAAC and the structural similarities of triazole to amide bond, and later presents most recent application of CuAAC as linkers and amide bond isosteres. Additional reviews in regards to NCL, Staudinger ligation, Diels-Alder reaction and SPAAC reactions were recently appraised by Chandrudu *et al.* [15] and Raibout *et al.* [16], van Berkel *et al.* [17], de Araujo *et al.* [18], and Debets *et al.* [19], respectively.

2. Copper (I) Catalyzed Alkyne-azide 1,3-Dipolarcycloaddition (CuAAC)

The formation of triazole was first discovered and reported by Authur Michael in 1893 [20]. In 1961, Rolf Hüisgen performed systematic studies on the nature of this reaction which was subsequently named the 1,3-dipolar cycloaddition (Scheme 3) [21]. The use of copper for the catalysis of Hüisgen azide-alkyne 1,3-dipolarcycloaddition (CuAAC), was first reported by L'Abbé in 1984 as a side reaction during the synthesis of azidoallenes complex [22]. No further investigation related to this observation was performed until in 2001, when the reaction was introduced by two independent laboratories led by Sharpless in the US and Meldal in Denmark [23,24]. CuAAC reaction, or 'click' reaction, is a regioselective copper (I) catalytic reaction between two terminal alkyne and azide functional groups, that give rise to 1,4-disubstituted 1,2,3-triazoles under mild conditions (Scheme 3, detailed possible mechanisms were discussed by Jones *et al.* and Himo *et al.*) [25–28]. Soon after its discovery, the CuAAC reaction became a common conjugation method, predominantly because this reaction is very robust, selective, and insensitive to the changes in pH and temperature. Currently, CuAAC is used in a wide range of applications in various disciples ranging from biomolecular and medicinal chemistry to polymer sciences [29–31].

Scheme 3. General reaction for CuAAC reaction producing a triazole ring.

Although the use of copper (I) is crucial for the cycloaddition reaction, in some cases, regulation of solvent and temperature (by heating in oil bath or microwave irradiation [32,33]), and introduction of ligand molecules or reducing agent can further push the reaction towards its desired product. Many copper (I) sources were tested and reported to catalyze the reaction. These include: copper (I) iodide (CuI), copper (I) bromide (CuBr), copper (II) sulfide ($CuSO_4$) or copper (0) (such as copper wire, powder and palette). For example, Meldal and co-workers used CuI and *N,N*-diisopropylethylamine (DIPEA, base to pre-activate the Cu^I by forming a copper-acetylene complex) in *N,N*-dimethylformamide (DMF) at 25 °C to yield 1,4-disubstituted 1,2,3-triazole structures [24]. An alternative method reported by Jang *et al.* involved the introduction of sodium ascorbate (NaAsc, a reducing agent that converted *in situ* copper (II), Cu^{II}, into copper (I), Cu^I) and substitution of DIPEA with pyridine also resulted in

formation of the triazole structure [34]. It was reported that removing the base from the reaction mixture usually did not significantly influence the reaction yield, thus base-free CuAAC is often reported [30,35,36]. The optional introduction of a copper ligand helped to enhance the progress of the reaction while protecting the Cu^I ions from oxidation. The versatility of this cycloaddition reaction was recently reviewed by Meldal [37].

Nevertheless, the application of CuAAC for biological compounds is controversial in regards to copper toxicity and the use of the reducing agent. For example there were reports that active copper species readily form radicals that can (partially) degrade or destroy peptides and protein complexes during CuAAC reactions, while in *in vitro* system, copper complexes may be taken up by cells, thus altering cellular metabolisms and functions [38,39]. To overcome these limitations, CuAAC-cell compatibility can be improved by either, the use of water-soluble ligands (e.g., bis-(L-histidine) [40]) or, in some cases, the use of accelerating CuI-ligands that allowed low CuI loading during catalytic reaction [41]. It has been also shown that copper wires can catalyze CuAAC reaction without need of the use of any additional ligands or reducing agents [30,42–44]. The toxicity of copper is well established; however, at the same time copper is essential element for human health, therefore the level of copper traces presented in the biologically relevant material need to be precisely determined (the recommended health standard level of copper is below 15 ppm) [45].

3. Structural Studies of Amide Bond and 1,4-Disubstituted Triazole

Amide bonds play a very important role in determining the bioactivity of a protein. Amino acids, the building block for proteins, are connected via the amide bonds. These bonds have restricted flexibility which allows distinct protein conformation. This structural conformation is further enhanced by intramolecular interaction between neighboring peptide chains as a result of hydrogen bonding, disulfide bridge formation, or hydrophobic interactions [1]. Turns in the backbone and intramolecular bonding result in proteins adopting a stable conformation (Figure 1). As a result, the incorporation of a single amino acid substitution at any point within the protein may result in altered structure. Thus, when an unnatural element is incorporated into peptide or protein, the ability of the synthetic constructs to mimic the native structure is very important to ensure the synthetic constructs maintain the desired biological activity. For example, it was discovered that single amino acid substitution in a synthetic luteinizing hormone releasing hormone (LHRH) drastically changes the peptide folding thus reduces the its activity [46,47]. Similarly, an antigen in subunit peptide vaccine needs to fold into its native conformation in order for the immune system to be able to recognize it and thus to produce a protective antibodies against the desired pathogen [48].

The importance of peptide and protein conformation limits the ability to easily substitute peptide bonds with unnatural elements. Peptide bonds can be replaced by mimicking functional groups (e.g., ester) [49,50]; however, not all of them, when incorporated in the sequence, are able to maintain secondary structure of the peptide (e.g., alkene) [51]. These facts prompted special interest in the application of triazole moiety for this purpose. The structural studies of amides and triazoles were first performed by Horne *et al*. in 2004 with the modification of pLI-GCN4 sequences, an α-helix coiled coil structure. They reported that although triazole substitution of the amide bond in a peptide backbone is longer by 1.1 Å (Figure 2), the modified peptide was still able to maintain its helical

structure [52]. Later, Brik *et al*. supported the idea that the 1,4-disubstituted triazole ring is suitable as a peptide surrogate or bioisostere [53]. The group experimented with triazole analogs of a peptide-based HIV protease inhibitor and found that the modified constructs maintained nanomolar inhibition activity. Crystallographic analyses of the constructs showed that the analogs were bound to the same enzyme pocket as the parent peptide. This finding further supported the observation that the triazole group displayed similar configuration to amide bond, mimicking trans-amide bond arrangement (Figure 2). Moreover, the triazole structure conferred almost similar polarizing properties to those found in amides, including the positions of hydrogen bonding donor and acceptor, and the similar electrophoretic dipole (5 Debye as compared to 4 Debye in amide bonds) [53]. In addition, the triazole ring is able to align itself with other amide groups via hydrogen bonds, in a similar manner to the alignment of an amide group to other amides in peptide secondary structure. The ring also adapted a three dimensional planar structure similar as an amide bond (Figure 2) [54–56]. However, unlike a native amide bond, triazoles are stable against proteolytic amide degradation. In sum, it is profound that structural modification of peptides and proteins using the CuAAC reaction could form an effective structural mimic of native amide bonds.

Figure 1. From amino acids to protein. (**A**) free amino acids; (**B**) primary structure (peptide bonds); (**C**) secondary structure (α-helix or β-sheet); (**D**) tertiary structure (whole protein or subdomain protein); (**E**) quaternary structure (multiple domain protein, HIV Protease, Protein Data Bank (PDB) number = 1HSG) [57].

Triazoles have been found to be excellent peptide bond substituents mainly due to their ability to increase peptides' biological stability *in vivo* while maintaining their activity. The natural occurring amide bond is very susceptible to various proteases [58]. Thus, substituting the amide bond with a triazole provides an alternative prospect to increase the bioavailability of the target compound *in vivo*.

The other advantage of triazole substitution is related to the CuAAC reaction itself. Unlike peptide coupling reactions, CuAAC is selective towards terminal azide and alkyne functional groups. This reaction can therefore be performed on unprotected peptides containing azide/alkyne groups [43]. Moreover, the CuAAC reaction is easy to perform with an ample range of reaction media and copper sources to choose from. Hence, the reaction condition can be altered to suit the conditions of the conjugation reaction. Despite the versatility of CuAAC and the triazole moiety mimicry of the amide bond, in most cases, CuAAC is primarily used for peptide-to-biomolecular conjugation.

Figure 2. Triazole as amide bond bioisosters. Arrow (⇨) represent hydrogen bonding sites. (PDB: 1HPV [59] and 1ZP8 [53]).

4. Application of CuAAC in Peptide Modifications

In 2002, the first application of the CuAAC reaction to form peptide derivatives was reported with the synthesis of peptidotriazoles and neoglycopeptide-linked-triazoles on solid support by Tornoe *et al*. [24]. A wide variety of azido groups were tested, affording compounds with crude purities ranging from 75% to 99% (Figure 3) [24]. The application of this reaction is not limited to conjugation between molecules (intermolecular coupling), but also within molecules (intramolecular coupling), thus the number of publications that have used this method have grown exponentially. Both inter and intramolecular conjugations have recently been added to the vast number of applications for this technique.

4.1. Intermolecular Linker

4.1.1. Single-Site Intermolecular Linker

One of the purposes of azide-alkyne single scaffold conjugation is tagging biomolecules. By labeling the peptides or protein with radioactive molecules (such as iodine-125 or fluorine-18 and their derivatives) or fluorescent compounds (green fluorescent protein, GFP), the target of interest can be

visualized via positron emission tomography (PET) or fluorescent imaging (fluorescent microscopy), respectively [60–65].

Figure 3. Examples of resin-bound peptidotriazoles constructs synthesized via CuAAC.

One example for such radiolabeled conjugation was to tag the tumour-targeting high molecular weight peptide, "pH (low) insertion peptide" (pHLIP) with radioactive [18]F. Direct labeling of large peptide using ^{18}F was synthetically challenging due to:

(1) Short half-life (low stability) of [18]F—thus the synthesis needed to be completed within a short time;

(2) Consideration of the safety of the operator working on the high gamma energy ^{18}F;

(3) Low purity resulting from direct coupling of ^{18}F, while the use of ^{18}F derivatives often required longer and more complicated synthetic procedures [66–68].

Although direct ^{18}F labeling was possible [65], however, the functional group in the peptide is barely compatible. Thus, CuAAC approach provides the best alternative for such conjugation to occur. Sutcliffe and co-workers successfully synthesized a 20 amino acids $\alpha_v\beta_6$ ^{18}F-radiolabeled peptide (medium MW ~2,000 Da, 10% yield) via the CuAAC reaction. However, the group experienced major difficulties when trying to conjugate the radiolabelled group to larger peptides via CuAAc [61,63]. A method to overcome this problem was reported by Daumar *et al.* who synthesized and conjugated a novel ^{18}F derivative to the pHLIP peptide via CuAAC reaction [61]. The initial CuAAC reaction between the ^{18}F-polyethylene glycol (PEG)-alkyne and pHLIP-azido groups under standard conditions (with copper (II) acetate, NaAsc in H_2O/MeCN (1:1 mixture) at 70 °C) was unsuccessful, despite the fact a similar reaction between ^{18}F-PEG-alkyne and RGD-azide peptide (MW ≈ 2,000 Da) proceeded smoothly [61,69]. Radiochemically active ^{18}F-pHLIP was obtained using a novel ^{18}F-alkyne prosthetic group ([18]Fluoro-pyridine alkyne) under standard conjugation conditions (13% pure yield within 85 min of preparation time) [61]. The use of less polar solvent mixture, *i.e.*, ethanol in H_2O (1:1), was

preferable for the CuAAC reaction of the ^{18}F derivative and pHLIP as compared to in H_2O/MeCN (1:1) mixture [61].

Octreotide is a peptide that has high receptor specificity to somatostatin receptors overexpressed in neuroendocrine tumours. The Reubi's group was the first to investigate somatostatin reception via a radiolabeled octreotide analog, [Tyr[3]]octreotate (TOCA) in 1985. The labeling was performed by iodination reaction at the tyrosine (Tyr[3]) side chain [65]. Conversely, the CuAAC reaction was used by Aboagye and colleague to conjugate a different radioactive compound (^{18}F) to the TOCA analog (Figure 4) [63]. Aboagye's group was the first to illustrate the application of CuAAC for tagging molecules through the conjugation of octreotide and a radioactive ^{18}F compound (instead of direct labeling of an amino acid within the construct). With the primary aim of reducing the synthesis time and increase TOCA binding affinity, five compounds were prepared using different alkynes analogs to create a novel library of radiolabeled TOCA analogs. The CuAAC synthesis using $CuSO_4$ (2 eq.) and NaAsc (2.2 eq.) at pH 5.0 at room temperature resulted in over 98% yield for two out of five compounds (**3** and **5**). Optimizing the reaction conditions by increasing the amount of $CuSO_4$ to 4 eq. and NaAsc to 4.4 eq. resulted in excellent yield (>98%) for the other three compounds (**1**, **2** and **4**). The group suggested that the position of the alkyne group located next to the amide group (**3** and **5**) enhanced the kinetics of the CuAAC reaction, while sequential glycol groups near the alkyne moiety reduced the CuAAC reaction rate (**1**) [63]. More detailed study into the influence of functional groups on the CuAAC reaction was reported by Golas *et al*. [70] and Fokin and Hein [71]. Affinity binding experiments with Reubi's compounds illustrated high binding affinity ($IC_{50} < 10$ nM) compared to control octreotide peptide ($IC_{50} = 15$ nM) [63]. This indicated high specificity of the compounds for the somatostatin receptor (CuAAC reaction did not cause loss of binding capacity).

Figure 4. ^{18}F-labeled TOCA analogs for tumor imaging. CuAAC condition: pH 5 acetate buffer, DMF and acetonitrile (MeCN) (8:3:10) at 25 °C plus; $CuSO_4$ and NaAsc.


Sewald and colleagues used arginine-aspartic acid-glycine (RDG) peptide as a targeting moiety for anticancer drug delivery [72]. The CuAAC reaction was used to conjugate cyclic RDG peptide

to cryptophycins, an apoptosis promoting and tubulin inhibitor depsipeptides (anticancer drug). Unfortunately, conjugation of RDG to cryptophycins reduces the drug's efficacy. Addition of fluorescein derivative to the drug further decreased its affinity to the microtubule in cancer cells due to steric hindrance. However, confocal analysis of the fluorescein-labeled constructs found that the presence of the cyclic peptide correlated with increased endocytosis by tumor cells. This illustrates the possibility to use the RDG peptide as a tumor-targeting moiety in peptide-drug conjugates. The CuAAC reaction was performed using copper (0) powder in *tert*-butanol/H$_2$O (2:1) mixture at room temperature. Copper powder was selected because solid copper is easily removed by filtration. The product yield was moderate with 68% and 43% yield for the non-fluorescent and fluorescently-labeled compounds, respectively, possibly due to short reaction time (~8 h) and the use of copper solid without a ligand [72].

Besides tagging, the CuAAC reaction was also used to modify the biological properties of peptide-oligonucleotide conjugates (POCs). Astakhova *et al.* conjugated enkephalin peptides to oligonucleotide (deoxyribonucleic acid, DNA) via CuAAC reaction to form POCs and the structure and properties of the oligonucleotides were examined [29]. The POCs were synthesized using CuSO$_4$ in the presence of tri(benzyltriazolylmethyl)amine (TBTA) ligand (1:1), NaAsc, aminoguanidine hydrochloride, dimethylsulfoxide (DMSO), 0.2 M carbonate buffer at pH 8.5, under argon atmosphere with vortexing for 12 to 24 h at room temperature [29]. The conjugation yields were over 95% and the method was highly reproducible. Thermal denaturing temperature (T$_m$) analysis showed the POCs remained stable at higher temperatures (up to 10 °C higher) than free oligonucleotides. Structural analysis of double POC conjugates resulted in structural stability of the POCs for up to 8 h in diluted human serum (90%) in comparison to a locked-nucleic acid DNA (locked-DNA) and unmodified DNA (control), which were degraded within 1 h and 30 min, respectively (Figure 5) [29].

Figure 5. Structural comparison between; (**A**) CuAAC locked-DNA; (**B**) locked-DNA; and (**C**) unmodified DNA. Red structures highlight the DNA backbone.

Furthermore, to improve the efficiency of fluorinated organophosphorous inhibitor (floronated OPI) targeted against serine hydrolases, Sokolova *et al.* constructed a library of small peptide analogs

conjugated to the inhibitor via CuAAC reaction (Table 1) [73,74]. Preliminary reactions were performed with $CuSO_4$ and NaAsc in chloroform $(CHCl_3)/H_2O$ at 10:1 mixture for 1 h at 40 °C. However, the yields were relatively modest (30%–65%) [74]. Prolonged reaction time (3 h) in 1:1 $CHCl_3/H_2O$ mixture improved the overall yield to over 75% [73]. Significant inhibition of the fluorinated OPI-peptide conjugates was observed (IC_{50} in milimolar range) with selective inhibition towards BChE and CaE subtype serine hydrolases [74].

Table 1. Selected fluoronated OPI-peptide constructs linked via CuAAC reaction.

Entry	R′	R1	R2	R3	R4	R5	Yield (%)
1	-CF_3	-CH_3	-CH_3	-CH_3	DMB	NHBoc	56
2	-CF_3	*i*-Pr	-H	-H	Bn	NHBoc	40
3	-CF_3	NHBoc	-H	-H	Bn	-CF_3	45
4	-CF_3	-H	-CH_3	-CH_3	Bn	-CF_3	45
5	-C(O)OCH_3	i-Pr	-H	-H	Bn	-CF_3	65
6	-C(O)OCH_3	i-Pr	-H	-H	Bn	NHBoc	55

Aggregation of elongated peptide during SPPS is often associated with poor yield and purity of the product [75]. With the aim to study the aggregation property of peptides, Perrier and colleagues worked with Alzheimer's disease-associated β-amyloid peptide (Aβ), which is known for its extreme aggregation, as a model peptide. The group used a microwave-assisted CuAAC reaction to conjugate short Aβ fibrils (sequence 16–20, FVLKFF) to different amphiphilic polymers: polar poly(hydroxylethyl acrylate) ($PHEA_{20}$), and less polar poly(*N*-isopropyl acrylamide) ($PNIPAAM_{20}$) [76]. Microwave-assisted CuAAC was chosen to destabilized peptide aggregation and further enhanced the CuAAC reaction. The reactions were performed using $CuSO_4$, NaAsc and DMF at 100 °C for 15 min. After completion of the conjugation, excess alkyne was removed by a secondary CuAAC reaction with the resin-bound azide. The final pure peptide-polymer conjugates were obtained in 43% yield. TEM images illustrated different structural assemblies which were highly dependent on aggregation time and concentration of the CuAAC products [76]. Attachment of the polymers generally disturbs the Aβ aggregation. For example, in the case of $PHEA_{20}$-Aβ conjugates, an 80% reduction in β-sheet formation was observed [76].

More recently, Brimble and colleagues synthesized novel Pam_2Cys constructs by conjugating Pam_2Cys to MUC1 peptide via CuAAC reaction (Figure 6) [77]. The CuAAC reaction was performed using CuI/ triethylphosphine $(P(OEt)_3)$/DIPEA in DMF for 30 min at room temperature [77].

Figure 6. (**A**) synthesis of azide modified Pam₂Cys via four steps: (i) piperidine, dichloromethane; (ii) imidazole-1-sulfonyl azide, potassium carbonate, methanol; (iii) palmatic acid (Pam), diisopropylcarboiimide, dimethylaminopyridine, tetrahydrofuran; (iv) trifluoroacetic acid; (**B**) CuAAC reaction of Pam₂Cys construct.


4.1.2. Multiple-Sites Intermolecular Conjugates

The CuAAC reaction allows single site conjugation between two molecules. However, multiple molecules can also be specifically conjugated to a single multi-site entity, and two molecules can be associated together using multiple conjugations.

Multiple biomolecule conjugation can be sub-categorized into dendritic, linear, cyclic or cross-linked assemblies (Figure 7). Although these conjugations are typically used in medicinal chemistry, dendrimer and linear assemblies have also been used in the field of vaccine development to enable antigen incorporation in a multiple antigen presenting (MAP) system. This system was shown to induce better immunological responses than a single antigen presenting system [78]. SPPS technique has been employed to synthesize MAP-based constructs. However, the peptides produced are usually difficult to purify to homogeneity. NCL of successive antigens is laborious, and attaching several epitopes at once can be difficult [13,14]. CuAAC provides an alternative to both stepwise SPPS and NCL to efficiently produce such constructs. In contrast to multivalent NCL, CuAAC proceeded faster, resulted in a higher yield, and the triazole product was stable in a biological environment [79].

Gupta *et al.* and Skwarczynski *et al.* exploited α- and ε-amino groups in the amino acid lysine as a branching unit for multiple conjugation sites for antigen presentations [43,79–81]. Using this technique, a set of azide- or alkyne-modified peptides were selected and conjugated to another peptide core. Conjugation efficiencies above 95% have been reported for CuAAC between functionalized azide and alkyne peptides. Skwarczynski *et al.* performed the CuAAC reaction in DMF, using copper wire as the copper source and heating at 50 °C without additional base, reducing agent or ligand. Within five hours, a 100% conversion was observed (Figure 8A) [43]. An alternative reaction was performed by Gupta *et al.* where CuSO₄ and NaAsc were used for the CuAAC reaction at room temperature. Quantitative conjugation for a less sterically hindered peptide alkyne was attained in a shorter time (1 h, Figure 8B) [79]. Both constructs were found to be immunologically active in an animal (murine) model, signifying the compatibility of CuAAC with multiple conjugate linkers [43,79,80].

Figure 7. Multiple conjugation strategy using CuAAC approach; (**A**) dendritic, (**B**) linear, (**C**) cyclic, (**D**) cross-linked.


Figure 8. Example of multiple triazole scaffolds synthesized via CuAAC; (**A**) lipid core peptide (LCP), (**B**) dendron scaffold, and (**C**) polymeric dendrimer.

As an alternative, Toth and colleagues conjugated multiple copies of peptide antigen based on group A streptococcus M protein and human papillomavirus-16 E7 peptide to polymer cores in two separate experiments [31,42,44,82]. The reaction was performed in DMF, using copper wire as the Cu^I source (as a result of comproportion reaction of copper ions) and heating at 50 °C overnight [25,83]. Based on elemental analysis of the resulting products, the efficiency of the CuAAC reaction was relatively good with a substitution ratio of around 75% (Figure 8C) [31,42,44,82]. The product self-assembled into particles which induced strong and antigen-specific cellular [44] and humoral immune responses [31,42,82].

Perrier and colleagues examined CuAAC conjugation efficiency between a cyclic β-sheet forming peptide and poly(butyl)acrylate (PBA) polymer [84]. The group observed steric effects that limited the reaction efficiency [84]. The conjugation was carried out using two- and four-arm cyclic functionalized peptides as illustrated in Figure 9. CuAAC reaction was performed using $CuSO_4$, NaAsc in either: DMF, trifluoroethanol (TFE), hexafluoroisopropanol (HFIP), TFE/DMF mixture, or HFIP/DMF mixture, and irradiated under microwave at 100 °C. Conjugation of polymers with high degree of grafting and polymerization (DP = 108) with a four-arm peptide showed a maximum of 55% conjugation efficiency. However, quantitative efficiency was reported using lower DP polymers (16 and 36) [84]. Reduced coupling efficiency observed by Skwarczynski *et al.* during the polymer-peptide conjugation may also result from steric effects associated with the large hydrophobic polymeric block [31,44].

Figure 9. Cyclic peptides scaffold for CuAAC bioconjugation with PBA polymer: (**A**) two-arm cyclic peptide, (**B**) four-arm cyclic peptide.

Arora and co-workers used triazoles as substitutes for native peptide backbone (triazolamer) [85,86]. A fully triazole-based peptide backbone was synthesized by the group after careful optimization of the reaction (Figure 10A) [85,86]. The group exploited one-pot triazole synthesis via sequential zinc (II) catalyzed diazoltransfer reaction and CuAAC reaction on solid support (PAM resin). The α-amino group of the amino acid was substituted with an azide moiety using amino acid methyl ester,

trifluoromethanesulfonyl azide (triflic azide), $CuSO_4$, and triethylamine at room temperature for three hours. The CuAAC reaction was performed by the addition of alkyne-derivatised α-amino acid, TBTA ligand and NaAsc to the initial reaction mixture and stirring at room temperature for 18 h. Upon repetition of above process the final product was obtained with an overall yield of 78% [85]. Interestingly, NMR analysis of the triazolamer suggested that the peptidomimic adopt β-strand-like structures, although the structural backbone lacks β-strand's hydrogen bond functionality [87]. The group further synthesized and evaluated triazolamer as human immunodeficiency virus-1 protease (HIVPR) inhibitor by synthesizing triazolamers that superimposed L-700,417 (Figure 10B), a peptide-based inhibitor that is widely used for HIVPR inhibition studies [87]. Five compounds (Figure 10C) showed high binding affinity (IC_{50} in micromolar range) compared to L-700,417 (IC_{50} = 670 μM) illustrating the viability of the triazolamers as peptidomimatic inhibitor.

Figure 10. (**A**) Amide backbone modification with triazole rings; (**B**) HIVPR inhibitor; (**C**) Triazolamer-based HIVPR inhibitors.

Ghadiri and co-workers synthesized heterocyclic pseudotetrapeptide via CuAAC reactions. Mimicking small β-turn molecules, the constructs were used as probes to assess the conformation of ligands to target the somatostatin receptor [88]. These 13- or 14-membered ring constructs each bore one or two triazole rings as peptide backbone surrogates (Figure 11A) [88]. Initially, linear peptides

were synthesized in solution phase and later were subjected to CuAAC reaction (CuI, 2,6-lutidine, DIPEA, TBTA in MeCN, stirred at room temperature for 12 h) to produce their cyclic counterparts. For the initial experiment, Ghandiri and co-workers synthesized a library of 16 cyclic isomeric compounds containing one triazole moiety. HPLC yields of 31% to 90% were obtained. Additionally, binding affinity experiments were carried out for the library. Although one compound showed high binding affinity ($IC_{50} < 200$ nM, Figure 11B), its affinity was lower than the parent peptide, SRIF-28 ($IC_{50} < 5$ nM, Figure 11C). Cyclic tetrapeptides without triazol moieties were not tested as the synthesis of the 12-membered ring resulted in very poor yield [88].

Figure 11. (**A**) General chemical structures of one and two triazole constructs. (**B**) Compound exhibited best somatostatin receptor binding experiment (IC_{50}). (**C**) Chemical structure of SRIF-28.

Jagasia *et al.* used CuAAC as a means to form a head-to-tail cyclodimerized construct on resin (with intact side-chain protecting groups, Figure 12). The group investigated some properties that could influence the formation of the cyclodimer pseudopeptide, as oppose to a monocyclic pseudopeptide which was mainly the aimed for some researchers [72,73,79,89,90]. Each CuAAC reaction was performed using CuI, DMSO:MeCN (1:3), at room temperature for 40 h [89]. It was concluded that cyclization of the peptide via CuAAC can be influenced by:

(a) The distance between the active groups (azide or alkyne) and the resin—as the distance increased, the yield of bicyclic product decreased;

(b) The distance between the active groups—a minimum of six amino acids promotes cyclodimerization;

(c) Solvent composition ratio—affects resin swelling and interstrand hydrogen bonding thus affecting the dimerization, and;

(d) The structural homolog of the peptide (α, β, γ *etc.*)—α and β homologs readily form the cyclodimer while γ homologs do not [89].

Figure 12. Head-to-tail CuAAC conjugation producing cyclodimer or cyclomonomer.

An example of crosslinking using CuAAC is illustrated in Figure 13. Kim and coworkers used polyaspartimide derivatives to construct a biocompatible, biodegradable three-dimensional hydrogel network that was cross-linked via the CuAAC reaction [91]. The reaction was performed using CuBr in the presence of *N,N,N',N',N''*-pentamethylenetriamine ligand. The polymer hydrogel was reported to form within minutes [91].

Figure 13. Formation of hydrogel based on multilinker conjugation via CuAAC.

4.2. Intramolecular Triazoles Linker

4.2.1. Side Chain Stapling/Macrocyclization

Peptides and proteins fold in a well-defined conformation in order to maintain their biological activity. Short peptides, such as APR-1 and J14$_i$ epitopes, have very distinct well-known drawbacks including susceptibility to protease degradation, poor bioavailability, and a highly flexible structure [43,92]. When used as vaccines, these peptides were poorly recognized by the immune system, resulting in weak antibody production. One of possible methods to improve the conformational stability of a peptide is by flanking it with helix promoting sequences, (e.g., GCN4 sequences) [92,93]. Alternatively, a side-chain stapling method can be applied. This method introduces conformational constraints in

peptides via side-chain-to-side-chain conjugation to stabilize peptide conformation and further improving peptides' stability against enzymatic degradation [56].

Previous, structural studies of 3_{10} helix based on a 4-aminopiperidine-4-carboxylic acid (Api) and α-aminoisobutyric acid (Aib) rich peptide was performed by Ousaka *et al*. Efforts to use a 'locked' 3_{10} helix approach via olefinic bridge and *p*-phenylenediacetic acid bridge were unsuccessful due to distortion of the native helix structure caused by the hydrophobic moiety of the olefinic and phenylenediacetic acid linkers [94,95]. Klaveness and co-workers used the CuAAC reaction to perform a novel stapling strategy with a Aib-rich model peptide [56]. The CuAAC stapling strategy was preferable because it established a hydrophilic 1,2,3-triazole moiety in the linker [56]. The model peptides were cyclized using CuI, P(OEt)$_3$, DIPEA in CH$_2$Cl$_2$ at room temperature for 42 h. The CuAAC reaction produced the desired intramolecularly-linked peptide in 83% yield. Crystallographic analysis of the constructs confirmed formation of a nearly perfect 3_{10} helical peptide (angle $\sigma^2 < 2^\circ$) [56].

Dawson and Ingale used side-chain-to-side-chain CuAAC conjugation to construct a modified HIV-1 gp41 peptide structure (SLW**JWFK(N$_3$)**ITNWLWYIK**AibKAib**KK, where **J** is propargylglycine, Pra) as illustrated in Figure 14. The side chain conjugation was performed between **J** and azidolysine, **K(N$_3$)**, located at 3_{10} helix position in order to stabilize the kink formed by the tryptophan and phenylalanine amino acids [90]. Dawson and Ingale initially faced difficulties during the cyclization using CuI, 2,6-lutidine in DMSO or DMF, even after a prolonged period of time. However, changing the reaction system to a CuBr/2,6-lutidine/DIPEA mixture resulted in 70% HPLC yield of product after 18 h. Analysis of the construct via circular dichroism showed the highest helicity content (based on mean residue ellipticity) for macrocycles with a 17- or 18- membered ring compared to their linear or 15 membered ring counterparts [90]. In comparison to the 3_{10} helix system, optimization in α-helix system performed by D'Ursi *et al*. illustrated that the best helical stabilization was achieved for constructs that possessed a 19 membered side-chain to side chain linkage [96].

Figure 14. 3_{10} helix side-chain-to-side-chain CuAAC cyclization.

More recently, Waters and Park used the CuAAC reaction to investigate the effect of cyclization on the structure, stability and activity of a β-hairpin tryptophan-lysine-tryptophan-lysine, WKWK peptide [97]. The wild type (wt) peptide was shown to be able to form β-hairpin structure, had low stability under protease treatment (three minutes), and was able to bind to adenosine triphosphate (ATP) nucleic acid [97]. The WKWK peptide was modified by placing azido and alkyl groups at several positions within the structure [98]. CuAAC reaction was performed in phosphate buffer (10 mM, pH 8), in the presence of tris-tri(methylazolyl) amine ligand, NaAsc, and

tetrakis(acetonitrile)copper(I)hexaflurophosphate at room temperature overnight. It was found that triazole linkage of the C-terminal side-chain to the N-terminal side-chain (Figure 15) maintained the β-structure more readily than the wt hairpin. Cyclization through the triazole linkage afforded improved proteolytic (>10 fold) and thermal stability. The ability of the macrocyclized construct to bind to ATP was better than its wt counterpart, with IC_{50} of 110 μM and 179 μM, respectively [97].

Figure 15. Structural improvement via side chain triazole linker.

4.2.2. Triazoles as Disulfide Bridge Substitutions

Disulfide bonds (bridges) play an important role in the integrity of folded peptides and proteins. For example, a 17 amino acid long antimicrobial peptide tachyplesin I (TP-1), contains two disulfide bridges that are crucial for correct β-hairpin folding and therefore its activity. Holland-Nell and Meldal used the CuAAC approach to substitute these two bridges with triazoles linkers by replacing two cysteines with Pra and the other two cysteines with either 2-amino-4-azidobutyric acid (Abu) or 5-azidonorvaline (Nva) [99]. They successfully formed correctly folded β-hairpin analogs, but the majority of the product was in the form of a misfolded globule-like structure (Figure 16, **B**:**C** in 1:7 ratio), following a CuAAC reaction using $CuSO_4$/tris(carboxyethyl)phosphine in H_2O for 16 h on resin. Microwave assisted CuAAC shifted the triazole formation, favoring the hairpin structure (**B**:**C** in 1:1.5 ratio). It was suggested that CuAAC reaction in an aqueous environment favored intramolecular hairpin folding while minimizing interchain bonding, as oligomerization was not observed at both conditions. Inhibition experiment (MIC) of the triazole analogs showed improved antibiotic activity against some bacterial species (*Escherichia coli*, *Bacillus subtilis* and *Salmonella typhimurium*) compared to wild type TP-1 peptide.

Figure 16. β-Hairpin structure of TP-1 peptide (in single letter amino acid code). (**A**) Native structure with two disulfide bonds. (**B**) Hairpin-like structure via triazole linkers. (**C**) Globule-like structure due to incorrect folding.

4.3. Other Applications

A unique application of the CuAAC reaction involves the use of a triazole moiety as a gas-phase cleavable linker for protein/peptide quantification under mass spectroscopy (MS)-ionization condition [100]. Although triazole is known for its stability as peptide/protein linker [101], Sohn *et al*. showed that it could be cleaved during MS measurement and form ionized species (reporter ion) which, in turn, was easily recorded by an ion detector (Figure 17). The CuAAC reaction to produced labeled peptide was performed using; $CuSO_4$, NaAsc, TBTA, in $DMSO/H_2O$ mixture, at room temperature for 4 h (yield = 69%–72%) [100].

Figure 17. Gas phase fragmentation of triazole into reporter ion.

5. Conclusions

The structural conformation of peptides and proteins are crucial for their biological activity. Chemical conjugation of biomolecules and amide-to-triazole substitutions via copper (I) catalyzed alkyne azide 1,3-dipolar cycloadditions (CuAACs) were shown to have the potential for improvement in medical applications such as, but not limited to, tumor-targeting/tumor-detecting ability as well as

the potential for improved drug stability and efficacy. These limitless capacities of CuAAC result from the selectivity of the reaction, ease to perform, and various choice of medium. To further exploit this reaction, detailed investigation into CuAAC transition states should be carried out to determine the 'true' reaction mechanism and therefore achieve better control of the reaction itself. Although CuAAC was shown to be a very robust reaction and is widely used in peptide chemistry, its application in protein chemistry is therefore possible. There are many opportunities for the expansion of CuAAC into the field of protein modification and beyond.

Acknowledgments

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Campbell, N.A.; Reece, J.B. *Biology*, 6th ed.; Pearson Education, Inc.: San Francisco, CA, USA, 2002;
   p. 1245.
2. Curtius, T. Ueber einige neue hippursaureanalog constituierte synthetisch dargestellte aminosauren. *J. Prakt. Chem.* **1882**, *26*, 145–208.
3. Fisher, E.; Fourneau, E. Ueber einige derivate des glykokolls. *Ber. Dtsch. Chem. Ges.* **1901**, *34*, 2868–2879.
4. Merrifield, R.B. Solid phase peptide synthesis.1. Synthesis of a tetrapeptide. *J. Am. Chem. Soc.* **1963**, *85*, 2149–2154.
5. Vigneaud, V.D.; Ressler, C.; Swan, J.M.; Roberts, C.W.; Katsoyannis, P.G. The synthesis of oxytocin. *J. Am. Chem. Soc.* **1954**, *76*, 3115–3121.
6. Kent, S.B. Total chemical synthesis of proteins. *Chem. Soc. Rev.* **2009**, *38*, 338–351.
7. Hofmann, K.; Yajima, H.; Yanaibara, N.; Liu, T.; Lande, S. Studies on polypeptides. XIII. The synthesis of a tricosapeptide posessing essentially the full biological activity of natural ACTH[1–3]. *J. Am. Chem. Soc.* **1961**, *83*, 486–487.
8. Kimura, T.; Takai, M.; Masui, Y.; Morikawa, T.; Sakakibara, S. Strategy for the synthesis of large peptides—an application to the total synthesis of human parathyroid-hormone [hpth(1–84)]. *Biopolymers* **1981**, *20*, 1823–1832.
9. Kemp, D.S.; Leung, S.L.; Kerkman, D.J. Models that demonstrate peptide-bond formation by prior thiol capture. 1. Capture by disulfide formation. *Tetrahedron Lett.* **1981**, *22*, 181–184.
10. Wieland, T.; Bokelmann, E.; Bauer, L.; Lang, H.U.; Lau, H. Über peptidsynthesen. 8. Bildung von s-haltigen peptiden durch intramolekulare wanderung von aminoacylresten. *Justus Liebigs Ann. Chem.* **1953**, *583*, 129–149.

11. Chen, J.; Wan, Q.; Yuan, Y.; Zhu, J.L.; Danishefsky, S.J. Native chemical ligation at valine: A contribution to peptide and glycopeptide synthesis. *Angew. Chem. Int. Ed. Engl.* **2008**, *47*, 8521–8524.

12. Tan, Z.; Shang, S.; Danishefsky, S.J. Insights into the finer issues of native chemical ligation: An approach to cascade ligations. *Angew. Chem. Int. Ed. Engl.* **2010**, *49*, 9500–9503.

13. Moyle, P.M.; Hari, Y.; Huang, N.; Olive, C.; Good, M.F.; Toth, I. A technique for the synthesis of highly-pure, mono-epitopic, multi-valent lipid core peptide vaccines. *Tetrahedron Lett.* **2007**, *48*, 4965–4967.

14. Fujita, Y.; Moyle, P.M.; Hieu, S.; Simerska, P.; Toth, I. Investigation toward multi-epitope vaccine candidates using native chemical ligation. *Biopolymers* **2008**, *90*, 624–632.

15. Chandrudu, S.; Simerska, P.; Toth, I. Chemical methods for peptide and protein production. *Molecules* **2013**, *18*, 4373–4388.

16. Raibaut, L.; Ollivier, N.; Melnyk, O. Sequential native peptide ligation strategies for total chemical protein synthesis. *Chem. Soc. Rev.* **2012**, *41*, 7001–7015.

17. Van Berkel, S.S.; van Eldijk, M.B.; van Hest, J.C.M. Staudinger ligation as a method for bioconjugation. *Angew. Chem. Int. Ed. Engl.* **2011**, *50*, 8806–8827.

18. De Araujo, A.D.; Palomo, J.M.; Cramer, J.; Seitz, O.; Alexandrov, K.; Waldmann, H. Diels-alder ligation of peptides and proteins. *Chemistry* **2006**, *12*, 6095–6109.

19. Debets, M.F.; van Berkel, S.S.; Dommerholt, J.; Dirks, A.T.; Rutjes, F.P.; van Delft, F.L. Bioconjugation with strained alkenes and alkynes. *Acc. Chem. Res.* **2011**, *44*, 805–815.

20. Michael, A. Ueber die einwirkung von diazobenzolimid auf acetylendicarbonsäuremethylester. *J. Prakt. Chem.* **1983**, *48*, 94–95.

21. Huisgen, R. Centenary lecture - 1,3-dipolar cycloadditions. *Proc. Chem. Soc. Lond.* **1961**, 357–396.

22. Labbe, G. Are azidocumulenes accessible. *Bull. Soc. Chim. Belg.* **1984**, *93*, 579–592.

23. Tornoe, C.W.; Christensen, C.; Meldal, M. Peptidotriazoles on solid phase: [1,2,3]-Triazoles by regiospecific copper(i)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides. *J. Org. Chem.* **2002**, *67*, 3057–3064.

24. Rostovtsev, V.V.; Green, L.G.; Fokin, V.V.; Sharpless, K.B. A stepwise huisgen cycloaddition process: Copper(i)-catalyzed regioselective "ligation" of azides and terminal alkynes. *Angew. Chem. Int. Ed. Engl.* **2002**, *41*, 2596–2599.

25. Himo, F.; Lovell, T.; Hilgraf, R.; Rostovtsev, V.V.; Noodleman, L.; Sharpless, K.B.; Fokin, V.V. Copper(i)-catalyzed synthesis of azoles. Dft study predicts unprecedented reactivity and intermediates. *J. Am. Chem. Soc.* **2005**, *127*, 210–216.

26. Kolb, H.C.; Sharpless, K.B. The growing impact of click chemistry on drug discovery. *Drug Discov. Today* **2003**, *8*, 1128–1137.

27. Meldal, M. Polymer "clicking" by cuaac reactions. *Macromol. Rapid Commun.* **2008**, *29*, 1016–1051.

28. Jones, G.O.; Ess, D.H.; Houk, K.N. Activation energies and reaction energetics for 1,3-dipolar cycloadditions of hydrazoic acid with c-c and c-n multiple bonds from high-accuracy and density functional quantum mechanical calculations. *Helv. Chim. Acta* **2005**, *88*, 1702–1710.

29. Golas, P.L.; Matyjaszewski, K. Marrying click chemistry with polymerization: Expanding the scope of polymeric materials. *Chem. Soc. Rev.* **2010**, *39*, 1338–1354.

30. Astakhova, I.K.; Hansen, L.H.; Vester, B.; Wengel, J. Peptide-lna oligonucleotide conjugates. *Org. Biomol. Chem.* **2013**, *11*, 4240–4249.

31. Ahmad Fuaad, A.A.; Jia, Z.; Hartas, J.; Ziora, Z.M.; Lin, I.C.; Moyle, P.M.; Batzloff, M.R.; Good, M.F.; Monteiro, M.J.; Skwarczynski, M.; *et al*. Polymer-peptide hybrids as a highly immunogenic single-dose nanovaccine. *Nanomedicine (Lond.)* **2013**, in press.

32. Hu, X.; Yan, L.; Xiao, H.; Li, H.; Jing, X. Application of microwave-assisted click chemistry in the preparation of functionalized copolymers for drug conjugation. *J. Appl. Polym. Sci.* **2012**, *127*, 3365–3373.

33. Barge, A.; Tagliapietra, S.; Binello, A.; Cravotto, G. Click chemistry under microwave or ultrasound irradiation. *Curr. Org. Chem.* **2011**, *15*, 189–203.

34. Jang, H.J.; Fafarman, A.; Holub, J.M.; Kirshenbaum, K. Click to fit: Versatile polyvalent display on a peptidomimetic scaffold. *Org. Lett.* **2005**, *7*, 1951–1954.

35. Li, Z.G.; Bittman, R. Synthesis and spectral properties of cholesterol- and fty720-containing boron dipyrromethene dyes. *J. Org. Chem.* **2007**, *72*, 8376–8382.

36. Molander, G.A.; Ham, J. Synthesis of functionalized organotrifluoroborates via the 1,3-dipolar cycloaddition of azides. *Org. Lett.* **2006**, *8*, 2767–2770.

37. Meldal, M.; Tornoe, C.W. Cu-catalyzed azide-alkyne cycloaddition. *Chem. Rev.* **2008**, *108*, 2952–3015.

38. Kennedy, D.C.; McKay, C.S.; Legault, M.C.B.; Danielson, D.C.; Blake, J.A.; Pegoraro, A.F.; Stolow, A.; Mester, Z.; Pezacki, J.P. Cellular consequences of copper complexes used to catalyze bioorthogonal click reactions. *J. Am. Chem. Soc.* **2011**, *133*, 17993–18001.

39. Van Hest, J.C.M.; van Delft, F.L. Protein modification by strain-promoted alkyne-azide cycloaddition. *ChemBioChem* **2011**, *12*, 1309–1312.

40. Uttamapinant, C.; Tangpeerachaikul, A.; Grecian, S.; Clarke, S.; Singh, U.; Slade, P.; Gee, K.R.; Ting, A.Y. Fast, cell-compatible click chemistry with copper-chelating azides for biomolecular labeling. *Angew. Chem. Int. Ed. Engl.* **2012**, *51*, 5852–5856.

41. Besanceney-Webler, C.; Jiang, H.; Zheng, T.Q.; Feng, L.; del Amo, D.S.; Wang, W.; Klivansky, L.M.; Marlow, F.L.; Liu, Y.; Wu, P. Increasing the efficacy of bioorthogonal click reactions for bioconjugation: A comparative study. *Angew. Chem. Int. Ed. Engl.* **2011**, *50*, 8051–8056.

42. Skwarczynski, M.; Zaman, M.; Urbani, C.N.; Lin, I.C.; Jia, Z.; Batzloff, M.R.; Good, M.F.; Monteiro, M.J.; Toth, I. Polyacrylate dendrimer nanoparticles: A self-adjuvanting vaccine delivery system. *Angew. Chem. Int. Ed. Engl.* **2010**, *49*, 5742–5745.

43. Skwarczynski, M.; Ahmad Fuaad, A.A.H.; Rustanti, L.; Ziora, Z.M.; Aqil, M.; Batzloff, M.R.; Good, M.F.; Toth, I. Group a streptococcus vaccine candidates based on the conserved conformational epitope from m protein. *Drug Deliv. Lett.* **2011**, *1*, 2–8.

44. Liu, T.Y.; Hussein, W.M.; Jia, Z.; Ziora, Z.M.; McMillan, N.A.; Monteiro, M.J.; Toth, I.; Skwarczynski, M. Self-adjuvanting polymer-peptide conjugates as therapeutic vaccine candidates against cervical cancer. *Biomacromolecules* **2013**, *14*, 2798–2806.

45. Macdonald, J.E.; Kelly, J.A.; Veinot, J.G.C. Iron/iron oxide nanoparticle sequestration of catalytic metal impurities from aqueous media and organic reaction products. *Langmuir* **2007**, *23*, 9543–9545.

46. Nikiforovich, G.V.; Marshall, G.R. Conformation-function relationships in lhrh analogs. 1. Conformations of lhrh peptide backbone. *Int. J. Pept. Protein Res.* **1993**, *42*, 171–180.

47. Nikiforovich, G.V.; Marshall, G.R. Conformation-function relationships in lhrh analogs. 2. Conformations of lhrh peptide agonists and antagonists. *Int. J. Pept. Protein Res.* **1993**, *42*, 181–193.

48. Brandt, E.R.; Sriprakash, K.S.; Hobb, R.I.; Hayman, W.A.; Zeng, W.G.; Batzloff, M.R.; Jackson, D.C.; Good, M.F. New multi-determinant strategy for a group a streptococcal vaccine designed for the australian aboriginal population. *Nat. Med.* **2000**, *6*, 455–459.

49. Choudhary, A.; Raines, R.T. An evaluation of peptide-bond isosteres. *ChemBioChem* **2011**, *12*, 1801–1807.

50. Baginski, M.; Piela, L.; Skolnick, J. The ethylene group as a peptide-bond mimicking unit—a theoretical conformational-analysis. *J. Comput. Chem.* **1993**, *14*, 471–477.

51. Jenkins, C.L.; Vasbinder, M.M.; Miller, S.J.; Raines, R.T. Peptide bond isosteres: Ester or (e)-alkene in the backbone of the collagen triple helix. *Org. Lett.* **2005**, *7*, 2619–2622.

52. Horne, W.S.; Yadav, M.K.; Stout, C.D.; Ghadiri, M.R. Heterocyclic peptide backbone modifications in an alpha-helical coiled coil. *J. Am. Chem. Soc.* **2004**, *126*, 15366–15367.

53. Brik, A.; Alexandratos, J.; Lin, Y.C.; Elder, J.H.; Olson, A.J.; Wlodawer, A.; Goodsell, D.S.; Wong, C.H. 1,2,3-triazole as a peptide surrogate in the rapid synthesis of hiv-1 protease inhibitors. *ChemBioChem* **2005**, *6*, 1167–1169.

54. Hou, J.L.; Liu, X.F.; Shen, J.; Zhao, G.L.; Wang, P.G. The impact of click chemistry in medicinal chemistry. *Expert Opin. Drug Dis.* **2012**, *7*, 489–501.

55. Li, X.C. Click to join peptides/proteins together. *Chem. Asian J.* **2011**, *6*, 2606–2616.

56. Jacobsen, O.; Maekawa, H.; Ge, N.H.; Gorbitz, C.H.; Rongved, P.; Ottersen, O.P.; Amiry-Moghaddam, M.; Klaveness, J. Stapling of a 3(10)-helix with click chemistry. *J. Org. Chem.* **2011**, *76*, 1228–1238.

57. Chen, Z.G.; Li, Y.; Chen, E.; Hall, D.L.; Darke, P.L.; Culberson, C.; Shafer, J.A.; Kuo, L.C. Crystal-structure at 1.9-angstrom resolution of human-immunodeficiency-virus (hiv)-ii protease complexed with l-735,524, an orally bioavailable inhibitor of the hiv proteases. *J. Biol. Chem.* **1994**, *269*, 26344–26348.

58. Saric, T.; Graef, C.I.; Goldberg, A.L. Pathway for degradation of peptides generated by proteasomes: A key role for thimet oligopeptidase and other metallopeptidases. *J. Biol. Chem.* **2004**, *279*, 46723–46732.

59. Kim, E.E.; Baker, C.T.; Dwyer, M.D.; Murcko, M.A.; Rao, B.G.; Tung, R.D.; Navia, M.A. Crystal-structure of hiv-1 protease in complex with vx-478, a potent and orally bioavailable inhibitor of the enzyme. *J. Am. Chem. Soc.* **1995**, *117*, 1181–1182.

60. Bejot, R.; Goggi, J.; Moonshi, S.S.; Robins, E.G. A practical synthesis of [f-18]ftrgd: An angiogenesis biomarker for pet. *J. Label. Compd. Radiopharm.* **2013**, *56*, 42–49.

61. Daumar, P.; Wanger-Baumann, C.A.; Pillarsetty, N.; Fabrizio, L.; Carlin, S.D.; Andreev, O.A.; Reshetnyak, Y.K.; Lewis, J.S. Efficient (18)f-labeling of large 37-amino-acid phlip peptide analogues and their biological evaluation. *Bioconjug. Chem.* **2012**, *23*, 1557–1566.

62. Gill, H.S.; Marik, J. Preparation of f-18-labeled peptides using the copper(i)-catalyzed azide-alkyne 1,3-dipolar cycloaddition. *Nat. Protoc.* **2011**, *6*, 1718–1725.

63. Iddon, L.; Leyton, J.; Indrevoll, B.; Glaser, M.; Robins, E.G.; George, A.J.T.; Cuthbertson, A.; Luthra, S.K.; Aboagye, E.O. Synthesis and *in vitro* evaluation of [f-18]fluoroethyl triazole labelled [tyr(3)]octreotate analogues using click chemistry. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 3122–3127.

64. Li, J.B.; Shi, L.L.; Jia, L.N.; Jiang, D.W.; Zhou, W.; Hu, W.Q.; Qi, Y.J.; Zhang, L. Radiolabeling of rgd peptide and preliminary biological evaluation in mice bearing u87mg tumors. *Bioorg. Med. Chem.* **2012**, *20*, 3850–3855.

65. Reubi, J.C. New specific radioligand for one subpopulation of brain somatostatin receptors. *Life Sci.* **1985**, *36*, 1829–1836.

66. Olberg, D.E.; Hjelstuen, O.K. Labeling strategies of peptides with f-18 for positron emission tomography. *Curr. Top. Med. Chem.* **2010**, *10*, 1669–1679.

67. Li, X.G.; Autio, A.; Ahtinen, H.; Helariutta, K.; Liljenback, H.; Jalkanen, S.; Roivainen, A.; Airaksinen, A.J. Translating the concept of peptide labeling with 5-deoxy-5-[f-18] fluororibose into preclinical practice: F-18-labeling of siglec-9 peptide for pet imaging of inflammation. *Chem. Commun.* **2013**, *49*, 3682–3684.

68. Dijkgraaf, I.; Terry, S.Y.A.; McBride, W.J.; Goldenberg, D.M.; Laverman, P.; Franssen, G.M.; Oyen, W.J.G.; Boerman, O.C. Imaging integrin alpha-v-beta-3 expression in tumors with an 18f-labeled dimeric rgd peptide. *Contrast Media Mol. Imaging* **2013**, *8*, 238–245.

69. Mamat, C.; Ramenda, T.; Wuest, F.R. Recent applications of click chemistry for the synthesis of radiotracers for molecular imaging. *Mini Rev. Org. Chem.* **2009**, *6*, 21–34.

70. Golas, P.L.; Tsarevsky, N.V.; Matyjaszewski, K. Structure-reactivity correlation in "click" chemistry: Substituent effect on azide reactivity. *Macromol. Rapid Commun.* **2008**, *29*, 1167–1171.

71. Hein, J.E.; Fokin, V.V. Copper-catalyzed azide-alkyne cycloaddition (cuaac) and beyond: New reactivity of copper(i) acetylides. *Chem. Soc. Rev.* **2010**, *39*, 1302–1315.

72. Nahrwold, M.; Weiss, C.; Bogner, T.; Mertink, F.; Conradi, J.; Sammet, B.; Palmisano, R.; Gracia, S.R.; Preusse, T.; Sewald, N. Conjugates of modified cryptophycins and rgd-peptides enter target cells by endocytosis. *J. Med. Chem.* **2013**, *56*, 1853–1864.

73. Sokolova, N.V.; Vorobyeva, D.V.; Osipov, S.N.; Vasilyeva, T.P.; Nenajdenko, V.G. Synthesis of alpha-trifluoromethyl-alpha-hydroxy acid-peptide conjugates via click chemistry. *Synth.—Stuttg.* **2012**, *44*, 130–136.

74. Sokolova, N.V.; Nenajdenko, V.G.; Sokolov, V.B.; Serebryakova, O.G.; Makhaeva, G.F. Synthesis and testing of trifluoromethyl-containing phosphonate-peptide conjugates as inhibitors of serine hydrolases. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 7216–7218.

75. Hussein, W.M.; Liu, T.Y.; Toth, I.; Skwarczynski, M. Microwave-assisted synthesis of difficult sequence-containing peptides using the isopeptide method. *Org. Biomol. Chem.* **2013**, *11*, 2370–2376.

76. Dehn, S.; Castelletto, V.; Hamley, I.W.; Perrier, S. Altering peptide fibrillization by polymer conjugation. *Biomacromolecules* **2012**, *13*, 2739–2747.

77. Yeung, H.; Lee, D.J.; Williams, G.M.; Harris, P.W.R.; Dunbar, R.P.; Brimble, M.A. A method for the generation of pam(2)cys-based lipopeptide mimics via cuaac click chemistry. *Synlett* **2012**, *11*, 1617–1620.

78. Fujita, Y.; Taguchi, H. Current status of multiple antigen-presenting peptide vaccine systems: Application of organic and inorganic nanoparticles. *Chem. Cent. J.* **2011**, *5*, doi:10.1186/1752-153X-5-48.

79. Gupta, K.; Singh, S.; Gupta, K.; Khan, N.; Sehgal, D.; Haridas, V.; Roy, R.P. A bioorthogonal chemoenzymatic strategy for defined protein dendrimer assembly. *ChemBioChem* **2012**, *13*, 2489–2494.

80. Skwarczynski, M.; Kamaruzaman, K.A.; Srinivasan, S.; Zaman, M.; Lin, I.C.; Batzloff, M.R.; Good, M.F.; Toth, I. M-protein-derived conformational peptide epitope vaccine candidate against group a streptococcus. *Curr. Drug Deliv.* **2013**, *10*, 39–45.

81. Skwarczynski, M.; Parhiz, B.H.; Soltani, F.; Srinivasan, S.; Kamaruzaman, K.A.; Lin, I.C.; Toth, I. Lipid peptide core nanoparticles as multivalent vaccine candidates against streptococcus pyogenes. *Aust. J. Chem.* **2012**, *65*, 35–39.

82. Zaman, M.; Skwarczynski, M.; Malcolm, J.M.; Urbani, C.N.; Jia, Z.; Batzloff, M.R.; Good, M.F.; Monteiro, M.J.; Toth, I. Self-adjuvanting polyacrylic nanoparticulate delivery system for group a streptococcus (gas) vaccine. *Nanomedicine* **2011**, *7*, 168–173.

83. Moen, A.; Nicholson, D.G. Reduction of copper(ii) with subsequent disproportionation of copper(i) during the hydrothermal syntheses of microporous silicoaluminium phosphates sapo-5 and sapo-11. *J. Chem. Soc. Faraday Trans.* **1995**, *91*, 3529–3535.

84. Poon, C.K.; Chapman, R.; Jolliffe, K.A.; Perrier, S. Pushing the limits of copper mediated azide-alkyne cycloaddition (cuaac) to conjugate polymeric chains to cyclic peptides. *Polym. Chem. UK* **2012**, *3*, 1820–1826.

85. Jochim, A.L.; Miller, S.E.; Angelo, N.G.; Arora, P.S. Evaluation of triazolamers as active site inhibitors of hiv-1 protease. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 6023–6026.

86. Angelo, N.G.; Arora, P.S. Solution- and solid-phase synthesis of triazole oligomers that display protein-like functionality. *J. Org. Chem.* **2007**, *72*, 7963–7967.

87. Angelo, N.G.; Arora, P.S. Nonpeptidic foldamers from amino acids: Synthesis and characterization of 1,3-substituted triazole oligomers. *J. Am. Chem. Soc.* **2005**, *127*, 17134–17135.

88. Beierle, J.M.; Horne, W.S.; van Maarseveen, J.H.; Waser, B.; Reubi, J.C.; Ghadiri, M.R. Conformationally homogeneous heterocyclic pseudotetrapeptides as three-dimensional scaffolds for rational drug design: Receptor-selective somatostatin analogues. *Angew. Chem. Int. Ed. Engl.* **2009**, *48*, 4725–4729.

89. Jagasia, R.; Holub, J.M.; Bollinger, M.; Kirshenbaum, K.; Finn, M.G. Peptide cyclization and cyclodimerization by cu-i-mediated azide-alkyne cycloaddition. *J. Org. Chem.* **2009**, *74*, 2964–2974.

90. Ingale, S.; Dawson, P.E. On resin side-chain cyclization of complex peptides using cuaac. *Org. Lett.* **2011**, *13*, 2822–2825.

91. Huynh, N.T.; Jeon, Y.S.; Zrinyi, M.; Kim, J.H. Preparation of click' hydrogels from polyaspartamide derivatives. *Polym. Int.* **2013**, *62*, 266–272.

92. Skwarczynski, M.; Dougall, A.M.; Khoshnejad, M.; Chandrudu, S.; Pearson, M.S.; Loukas, A.; Toth, I. Peptide-based subunit vaccine against hookworm infection. *PLoS One* **2012**, *7*, doi:10.1371/journal.pone.0046870.

93. Zhong, W.; Skwarczynski, M.; Toth, I. Lipid core peptide system for gene, drug, and vaccine delivery. *Aust. J. Chem.* **2009**, *62*, 956–967.

94. Schievano, E.; Pagano, K.; Mammi, S.; Peggion, E. Conformational studies of aib-rich peptides containing lactam-bridged side chains: Evidence of 3(10)-helix formation. *Biopolymers* **2005**, *80*, 294–302.

95. Ousaka, N.; Sato, T.; Kuroda, R. Intramolecular crosslinking of an optically inactive 3(10)-helical peptide: Stabilization of structure and helix sense. *J. Am. Chem. Soc.* **2008**, *130*, 463–465.

96. Scrima, M.; Le Chevalier-Isaad, A.; Rovero, P.; Papini, A.M.; Chorev, M.; D'Ursi, A.M. Cu-i-catalyzed azide-alkyne intramolecular i-to-(i+4) side-chain-to-side-chain cyclization promotes the formation of helix-like secondary structures. *Eur. J. Org. Chem.* **2010**, *2010*, 446–457.

97. Park, J.H.; Waters, M.L. Positional effects of click cyclization on beta-hairpin structure, stability, and function. *Org. Biomol. Chem.* **2013**, *11*, 69–77.

98. Butterfield, S.M.; Sweeney, M.M.; Waters, M.L. The recognition of nucleotides with model ss-hairpin receptors: Investigation of critical contacts and nucleotide selectivity. *J. Org. Chem.* **2005**, *70*, 1105–1114.

99. Holland-Nell, K.; Meldal, M. Maintaining biological activity by using triazoles as disufide bond mimetics. *Angew. Chem. Int. Ed. Engl.* **2011**, *50*, 5204–5206.

100. Sohn, C.H.; Lee, J.E.; Sweredoski, M.J.; Graham, R.L.; Smith, G.T.; Hess, S.; Czerwieniec, G.; Loo, J.A.; Deshaies, R.J.; Beauchamp, J.L. Click chemistry facilitates formation of reporter ions and simplified synthesis of amine-reactive multiplexed isobaric tags for protein quantification. *J. Am. Chem. Soc.* **2012**, *134*, 2672–2680.

101. Chowdhury, S.M.; Du, X.X.; Tolic, N.; Wu, S.; Moore, R.J.; Mayer, M.U.; Smith, R.D.; Adkins, J.N. Identification of cross-linked peptides after click-based enrichment using sequential collision-induced dissociation and electron transfer dissociation tandem mass spectrometry. *Anal. Chem.* **2009**, *81*, 5524–5532.